#151429

Anti-CD19 [BU12] mAb

Cat. #151429

Anti-CD19 [BU12] mAb

Cat. #: 151429

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: CD19

Class: Monoclonal

Application: FACS ; IHC ; IP

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Roy Jefferis

Institute: University of Birmingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-CD19 [BU12] mAb
  • Alternate name: CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4
  • Clone: BU12
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IP
  • Description: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.
  • Immunogen: Human EB-4 Burkitt's lymphoma cell line
  • Isotype: IgG1

Target Details

  • Target: CD19
  • Target background: CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase.

Applications

  • Application: FACS ; IHC ; IP

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Bortolotti et al. 2016. Toxins (Basel). 8(6):. PMID: 27338475.
  • High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin.
  • Flavell et al. 2006. Br J Haematol. 134(2):157-70. PMID: 16771848.
  • The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
  • Behr et al. 1995. J Exp Med. 182(5):1191-9. PMID: 7595190.
  • Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin.
  • Schlossman SF. et al. 1995. Leucocyte Typing V. Oxford University Press
  • Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.
  • CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used.